Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases

Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases

<b>Background:</b> Vedolizumab (vedo) is effective for induction and maintenance of remission in adults with inflammatory bowel disease (IBD). Pediatric data are still limited, especially for the youngest children with very early onset disease (VEO-IBD). The aim of this study was to asse...

Full description

Bibliographic Details
Main Authors: Sylwia Fabiszewska, Edyta Derda, Edyta Szymanska, Marcin Osiecki, Jaroslaw Kierkus
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Journal of Clinical Medicine
Subjects:
premedication
infusion reaction
infliximab
inflammatory bowel disease
Online Access:https://www.mdpi.com/2077-0383/10/13/2997

Internet

https://www.mdpi.com/2077-0383/10/13/2997

Similar Items